nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—Protein Kinase Inhibitors—Vandetanib—thyroid cancer	0.38	1	CiPCiCtD
Pazopanib—kidney cancer—thyroid cancer	0.224	1	CtDrD
Pazopanib—BMPR1B—Vandetanib—thyroid cancer	0.0214	0.0764	CbGbCtD
Pazopanib—FLT4—Vandetanib—thyroid cancer	0.0179	0.0639	CbGbCtD
Pazopanib—PLK4—Vandetanib—thyroid cancer	0.0179	0.0639	CbGbCtD
Pazopanib—KDR—Vandetanib—thyroid cancer	0.0155	0.0552	CbGbCtD
Pazopanib—EPHB6—Vandetanib—thyroid cancer	0.0137	0.0488	CbGbCtD
Pazopanib—LYN—Vandetanib—thyroid cancer	0.0137	0.0488	CbGbCtD
Pazopanib—FLT1—Sorafenib—thyroid cancer	0.0129	0.0461	CbGbCtD
Pazopanib—AURKC—Sorafenib—thyroid cancer	0.0129	0.0461	CbGbCtD
Pazopanib—STK10—Vandetanib—thyroid cancer	0.0123	0.0439	CbGbCtD
Pazopanib—PDGFRB—Vandetanib—thyroid cancer	0.0112	0.0399	CbGbCtD
Pazopanib—LCK—Vandetanib—thyroid cancer	0.0112	0.0399	CbGbCtD
Pazopanib—MAP2K5—Vandetanib—thyroid cancer	0.0112	0.0399	CbGbCtD
Pazopanib—FLT4—Sorafenib—thyroid cancer	0.0108	0.0385	CbGbCtD
Pazopanib—FGFR1—Sorafenib—thyroid cancer	0.0108	0.0385	CbGbCtD
Pazopanib—MAP3K19—Vandetanib—thyroid cancer	0.0103	0.0367	CbGbCtD
Pazopanib—KDR—Sorafenib—thyroid cancer	0.00932	0.0333	CbGbCtD
Pazopanib—EPHB6—Sorafenib—thyroid cancer	0.00824	0.0294	CbGbCtD
Pazopanib—PDGFRA—Sorafenib—thyroid cancer	0.00741	0.0264	CbGbCtD
Pazopanib—KIT—Sorafenib—thyroid cancer	0.00741	0.0264	CbGbCtD
Pazopanib—STK10—Sorafenib—thyroid cancer	0.00741	0.0264	CbGbCtD
Pazopanib—CSF1R—Sorafenib—thyroid cancer	0.00741	0.0264	CbGbCtD
Pazopanib—MAP2K5—Sorafenib—thyroid cancer	0.00674	0.0241	CbGbCtD
Pazopanib—PDGFRB—Sorafenib—thyroid cancer	0.00674	0.0241	CbGbCtD
Pazopanib—MAP3K19—Sorafenib—thyroid cancer	0.0062	0.0221	CbGbCtD
Pazopanib—UGT1A1—Sorafenib—thyroid cancer	0.00222	0.00794	CbGbCtD
Pazopanib—ABCG2—Vandetanib—thyroid cancer	0.00203	0.00725	CbGbCtD
Pazopanib—ABCG2—Sorafenib—thyroid cancer	0.00122	0.00437	CbGbCtD
Pazopanib—ABCG2—Doxorubicin—thyroid cancer	0.000742	0.00265	CbGbCtD
Pazopanib—CYP2C8—Sorafenib—thyroid cancer	0.000651	0.00233	CbGbCtD
Pazopanib—CYP1A2—Sorafenib—thyroid cancer	0.000504	0.0018	CbGbCtD
Pazopanib—ABCB1—Sorafenib—thyroid cancer	0.000441	0.00157	CbGbCtD
Pazopanib—MAP3K9—thyroid gland—thyroid cancer	0.000441	0.019	CbGeAlD
Pazopanib—CYP3A4—Vandetanib—thyroid cancer	0.000438	0.00157	CbGbCtD
Pazopanib—CYP2D6—Sorafenib—thyroid cancer	0.000416	0.00148	CbGbCtD
Pazopanib—SH2B3—trachea—thyroid cancer	0.000394	0.017	CbGeAlD
Pazopanib—MAP3K9—head—thyroid cancer	0.000391	0.0169	CbGeAlD
Pazopanib—FGF1—neck—thyroid cancer	0.00038	0.0164	CbGeAlD
Pazopanib—PI4KB—saliva-secreting gland—thyroid cancer	0.000378	0.0163	CbGeAlD
Pazopanib—ITK—thyroid gland—thyroid cancer	0.000363	0.0157	CbGeAlD
Pazopanib—FGFR2—neck—thyroid cancer	0.000359	0.0155	CbGeAlD
Pazopanib—FLT1—neck—thyroid cancer	0.000332	0.0143	CbGeAlD
Pazopanib—PIP4K2C—saliva-secreting gland—thyroid cancer	0.000332	0.0143	CbGeAlD
Pazopanib—TAOK1—thyroid gland—thyroid cancer	0.000331	0.0143	CbGeAlD
Pazopanib—SH2B3—thyroid gland—thyroid cancer	0.000312	0.0134	CbGeAlD
Pazopanib—AURKC—thyroid gland—thyroid cancer	0.000307	0.0132	CbGeAlD
Pazopanib—STK36—trachea—thyroid cancer	0.000296	0.0128	CbGeAlD
Pazopanib—TAOK1—head—thyroid cancer	0.000294	0.0127	CbGeAlD
Pazopanib—PI4KB—trachea—thyroid cancer	0.000292	0.0126	CbGeAlD
Pazopanib—LIMK2—trachea—thyroid cancer	0.000286	0.0123	CbGeAlD
Pazopanib—KDR—neck—thyroid cancer	0.000281	0.0121	CbGeAlD
Pazopanib—FGFR2—saliva-secreting gland—thyroid cancer	0.00028	0.0121	CbGeAlD
Pazopanib—SH2B3—head—thyroid cancer	0.000276	0.0119	CbGeAlD
Pazopanib—MAP3K9—lymph node—thyroid cancer	0.000274	0.0118	CbGeAlD
Pazopanib—AURKC—head—thyroid cancer	0.000272	0.0117	CbGeAlD
Pazopanib—ABCB1—Doxorubicin—thyroid cancer	0.000268	0.000956	CbGbCtD
Pazopanib—STK16—thyroid gland—thyroid cancer	0.000265	0.0114	CbGeAlD
Pazopanib—CYP3A4—Sorafenib—thyroid cancer	0.000264	0.000944	CbGbCtD
Pazopanib—RIOK2—thyroid gland—thyroid cancer	0.000261	0.0112	CbGeAlD
Pazopanib—FLT1—saliva-secreting gland—thyroid cancer	0.000259	0.0112	CbGeAlD
Pazopanib—BMPR1B—thyroid gland—thyroid cancer	0.000258	0.0111	CbGeAlD
Pazopanib—EPHB6—saliva-secreting gland—thyroid cancer	0.000256	0.011	CbGeAlD
Pazopanib—PIP4K2C—trachea—thyroid cancer	0.000256	0.011	CbGeAlD
Pazopanib—CYP2D6—Doxorubicin—thyroid cancer	0.000252	0.0009	CbGbCtD
Pazopanib—KIT—neck—thyroid cancer	0.000249	0.0107	CbGeAlD
Pazopanib—TAOK3—saliva-secreting gland—thyroid cancer	0.000244	0.0105	CbGeAlD
Pazopanib—PDGFRB—neck—thyroid cancer	0.000243	0.0105	CbGeAlD
Pazopanib—STK16—head—thyroid cancer	0.000235	0.0101	CbGeAlD
Pazopanib—STK36—thyroid gland—thyroid cancer	0.000234	0.0101	CbGeAlD
Pazopanib—LYN—head—thyroid cancer	0.000233	0.01	CbGeAlD
Pazopanib—FGFR3—head—thyroid cancer	0.000231	0.00997	CbGeAlD
Pazopanib—RIOK2—head—thyroid cancer	0.000231	0.00997	CbGeAlD
Pazopanib—PI4KB—thyroid gland—thyroid cancer	0.000231	0.00994	CbGeAlD
Pazopanib—MAP3K19—head—thyroid cancer	0.000229	0.00987	CbGeAlD
Pazopanib—BMPR1B—head—thyroid cancer	0.000229	0.00987	CbGeAlD
Pazopanib—LCK—trachea—thyroid cancer	0.000227	0.00979	CbGeAlD
Pazopanib—LIMK2—thyroid gland—thyroid cancer	0.000226	0.00976	CbGeAlD
Pazopanib—ITK—lymph node—thyroid cancer	0.000226	0.00973	CbGeAlD
Pazopanib—KDR—saliva-secreting gland—thyroid cancer	0.000219	0.00945	CbGeAlD
Pazopanib—MAP2K5—saliva-secreting gland—thyroid cancer	0.000219	0.00945	CbGeAlD
Pazopanib—STK36—head—thyroid cancer	0.000208	0.00896	CbGeAlD
Pazopanib—TAOK1—lymph node—thyroid cancer	0.000206	0.00886	CbGeAlD
Pazopanib—PI4KB—head—thyroid cancer	0.000205	0.00882	CbGeAlD
Pazopanib—FLT4—thyroid gland—thyroid cancer	0.000203	0.00877	CbGeAlD
Pazopanib—PIP4K2C—thyroid gland—thyroid cancer	0.000202	0.00872	CbGeAlD
Pazopanib—LIMK2—head—thyroid cancer	0.000201	0.00866	CbGeAlD
Pazopanib—FGFR1—thyroid gland—thyroid cancer	0.000201	0.00865	CbGeAlD
Pazopanib—FLT1—trachea—thyroid cancer	0.0002	0.00862	CbGeAlD
Pazopanib—EPHB6—trachea—thyroid cancer	0.000198	0.00852	CbGeAlD
Pazopanib—KIT—saliva-secreting gland—thyroid cancer	0.000194	0.00837	CbGeAlD
Pazopanib—SH2B3—lymph node—thyroid cancer	0.000194	0.00834	CbGeAlD
Pazopanib—MAP3K2—thyroid gland—thyroid cancer	0.000192	0.00827	CbGeAlD
Pazopanib—AURKC—lymph node—thyroid cancer	0.000191	0.00821	CbGeAlD
Pazopanib—PDGFRB—saliva-secreting gland—thyroid cancer	0.00019	0.00818	CbGeAlD
Pazopanib—TAOK3—trachea—thyroid cancer	0.000189	0.00813	CbGeAlD
Pazopanib—PDGFRA—trachea—thyroid cancer	0.000187	0.00808	CbGeAlD
Pazopanib—PLK4—Doxorubicin—Epirubicin—thyroid cancer	0.000182	0.26	CbGdCrCtD
Pazopanib—PLK4—Idarubicin—Epirubicin—thyroid cancer	0.000182	0.26	CbGdCrCtD
Pazopanib—FGF1—thyroid gland—thyroid cancer	0.000181	0.00779	CbGeAlD
Pazopanib—FLT4—head—thyroid cancer	0.000181	0.00778	CbGeAlD
Pazopanib—LCK—thyroid gland—thyroid cancer	0.00018	0.00774	CbGeAlD
Pazopanib—PIP4K2C—head—thyroid cancer	0.00018	0.00774	CbGeAlD
Pazopanib—PLK4—lymph node—thyroid cancer	0.000174	0.00751	CbGeAlD
Pazopanib—FGFR2—thyroid gland—thyroid cancer	0.000171	0.00736	CbGeAlD
Pazopanib—MAP3K2—head—thyroid cancer	0.00017	0.00733	CbGeAlD
Pazopanib—KDR—trachea—thyroid cancer	0.000169	0.00729	CbGeAlD
Pazopanib—MAP2K5—trachea—thyroid cancer	0.000169	0.00729	CbGeAlD
Pazopanib—PLK4—Epirubicin—Doxorubicin—thyroid cancer	0.000168	0.24	CbGdCrCtD
Pazopanib—PLK4—Idarubicin—Doxorubicin—thyroid cancer	0.000168	0.24	CbGdCrCtD
Pazopanib—CSF1R—trachea—thyroid cancer	0.000165	0.00711	CbGeAlD
Pazopanib—STK16—lymph node—thyroid cancer	0.000165	0.00709	CbGeAlD
Pazopanib—RIOK2—lymph node—thyroid cancer	0.000162	0.00698	CbGeAlD
Pazopanib—BMPR1B—lymph node—thyroid cancer	0.00016	0.00691	CbGeAlD
Pazopanib—FGF1—head—thyroid cancer	0.00016	0.00691	CbGeAlD
Pazopanib—CYP3A4—Doxorubicin—thyroid cancer	0.00016	0.000573	CbGbCtD
Pazopanib—FLT1—thyroid gland—thyroid cancer	0.000158	0.00682	CbGeAlD
Pazopanib—EPHB6—thyroid gland—thyroid cancer	0.000156	0.00674	CbGeAlD
Pazopanib—FGFR2—head—thyroid cancer	0.000151	0.00653	CbGeAlD
Pazopanib—KIT—trachea—thyroid cancer	0.00015	0.00646	CbGeAlD
Pazopanib—STK10—thyroid gland—thyroid cancer	0.00015	0.00645	CbGeAlD
Pazopanib—TAOK3—thyroid gland—thyroid cancer	0.000149	0.00643	CbGeAlD
Pazopanib—PDGFRA—thyroid gland—thyroid cancer	0.000148	0.00639	CbGeAlD
Pazopanib—PDGFRB—trachea—thyroid cancer	0.000146	0.00631	CbGeAlD
Pazopanib—STK36—lymph node—thyroid cancer	0.000146	0.00627	CbGeAlD
Pazopanib—PI4KB—lymph node—thyroid cancer	0.000143	0.00617	CbGeAlD
Pazopanib—LIMK2—lymph node—thyroid cancer	0.000141	0.00606	CbGeAlD
Pazopanib—FLT1—head—thyroid cancer	0.00014	0.00605	CbGeAlD
Pazopanib—EPHB6—head—thyroid cancer	0.000139	0.00598	CbGeAlD
Pazopanib—KDR—thyroid gland—thyroid cancer	0.000134	0.00576	CbGeAlD
Pazopanib—MAP2K5—thyroid gland—thyroid cancer	0.000134	0.00576	CbGeAlD
Pazopanib—STK10—head—thyroid cancer	0.000133	0.00573	CbGeAlD
Pazopanib—TAOK3—head—thyroid cancer	0.000132	0.0057	CbGeAlD
Pazopanib—PDGFRA—head—thyroid cancer	0.000132	0.00567	CbGeAlD
Pazopanib—CSF1R—thyroid gland—thyroid cancer	0.000131	0.00563	CbGeAlD
Pazopanib—FLT4—lymph node—thyroid cancer	0.000126	0.00545	CbGeAlD
Pazopanib—PIP4K2C—lymph node—thyroid cancer	0.000126	0.00542	CbGeAlD
Pazopanib—FGFR1—lymph node—thyroid cancer	0.000125	0.00537	CbGeAlD
Pazopanib—MAP3K2—lymph node—thyroid cancer	0.000119	0.00514	CbGeAlD
Pazopanib—KDR—head—thyroid cancer	0.000119	0.00511	CbGeAlD
Pazopanib—MAP2K5—head—thyroid cancer	0.000119	0.00511	CbGeAlD
Pazopanib—KIT—thyroid gland—thyroid cancer	0.000119	0.00511	CbGeAlD
Pazopanib—CSF1R—head—thyroid cancer	0.000116	0.00499	CbGeAlD
Pazopanib—PDGFRB—thyroid gland—thyroid cancer	0.000116	0.00499	CbGeAlD
Pazopanib—FGF1—lymph node—thyroid cancer	0.000112	0.00484	CbGeAlD
Pazopanib—LCK—lymph node—thyroid cancer	0.000112	0.00481	CbGeAlD
Pazopanib—ABCG2—saliva-secreting gland—thyroid cancer	0.000107	0.0046	CbGeAlD
Pazopanib—KIT—head—thyroid cancer	0.000105	0.00453	CbGeAlD
Pazopanib—PDGFRB—head—thyroid cancer	0.000103	0.00443	CbGeAlD
Pazopanib—FLT1—lymph node—thyroid cancer	9.83e-05	0.00424	CbGeAlD
Pazopanib—EPHB6—lymph node—thyroid cancer	9.72e-05	0.00419	CbGeAlD
Pazopanib—STK10—lymph node—thyroid cancer	9.3e-05	0.00401	CbGeAlD
Pazopanib—TAOK3—lymph node—thyroid cancer	9.27e-05	0.00399	CbGeAlD
Pazopanib—PDGFRA—lymph node—thyroid cancer	9.21e-05	0.00397	CbGeAlD
Pazopanib—KDR—lymph node—thyroid cancer	8.31e-05	0.00358	CbGeAlD
Pazopanib—MAP2K5—lymph node—thyroid cancer	8.31e-05	0.00358	CbGeAlD
Pazopanib—CSF1R—lymph node—thyroid cancer	8.11e-05	0.00349	CbGeAlD
Pazopanib—KIT—lymph node—thyroid cancer	7.36e-05	0.00317	CbGeAlD
Pazopanib—PDGFRB—lymph node—thyroid cancer	7.19e-05	0.0031	CbGeAlD
Pazopanib—ABCG2—thyroid gland—thyroid cancer	6.51e-05	0.0028	CbGeAlD
Pazopanib—CYP1A2—thyroid gland—thyroid cancer	6.26e-05	0.0027	CbGeAlD
Pazopanib—Cough—Sorafenib—thyroid cancer	4.7e-05	0.000905	CcSEcCtD
Pazopanib—Asthenia—Vandetanib—thyroid cancer	4.67e-05	0.0009	CcSEcCtD
Pazopanib—Skin discolouration—Doxorubicin—thyroid cancer	4.66e-05	0.000898	CcSEcCtD
Pazopanib—Rectal haemorrhage—Doxorubicin—thyroid cancer	4.66e-05	0.000898	CcSEcCtD
Pazopanib—Hypertension—Sorafenib—thyroid cancer	4.65e-05	0.000895	CcSEcCtD
Pazopanib—Hyperbilirubinaemia—Doxorubicin—thyroid cancer	4.63e-05	0.000892	CcSEcCtD
Pazopanib—Pruritus—Vandetanib—thyroid cancer	4.61e-05	0.000887	CcSEcCtD
Pazopanib—Musculoskeletal pain—Epirubicin—thyroid cancer	4.61e-05	0.000887	CcSEcCtD
Pazopanib—Arthralgia—Sorafenib—thyroid cancer	4.58e-05	0.000883	CcSEcCtD
Pazopanib—Myalgia—Sorafenib—thyroid cancer	4.58e-05	0.000883	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	4.55e-05	0.000877	CcSEcCtD
Pazopanib—Pulmonary embolism—Epirubicin—thyroid cancer	4.55e-05	0.000877	CcSEcCtD
Pazopanib—Phosphatase alkaline increased—Epirubicin—thyroid cancer	4.55e-05	0.000877	CcSEcCtD
Pazopanib—Hiccups—Epirubicin—thyroid cancer	4.55e-05	0.000877	CcSEcCtD
Pazopanib—Dry mouth—Sorafenib—thyroid cancer	4.48e-05	0.000863	CcSEcCtD
Pazopanib—Diarrhoea—Vandetanib—thyroid cancer	4.46e-05	0.000858	CcSEcCtD
Pazopanib—Blood bilirubin increased—Doxorubicin—thyroid cancer	4.45e-05	0.000857	CcSEcCtD
Pazopanib—Melaena—Epirubicin—thyroid cancer	4.44e-05	0.000856	CcSEcCtD
Pazopanib—Creatinine increased—Doxorubicin—thyroid cancer	4.42e-05	0.000852	CcSEcCtD
Pazopanib—Infection—Sorafenib—thyroid cancer	4.36e-05	0.000841	CcSEcCtD
Pazopanib—Skin exfoliation—Epirubicin—thyroid cancer	4.34e-05	0.000837	CcSEcCtD
Pazopanib—Shock—Sorafenib—thyroid cancer	4.32e-05	0.000832	CcSEcCtD
Pazopanib—Nervous system disorder—Sorafenib—thyroid cancer	4.31e-05	0.00083	CcSEcCtD
Pazopanib—Dizziness—Vandetanib—thyroid cancer	4.31e-05	0.000829	CcSEcCtD
Pazopanib—Thrombocytopenia—Sorafenib—thyroid cancer	4.3e-05	0.000828	CcSEcCtD
Pazopanib—Blood urea increased—Epirubicin—thyroid cancer	4.3e-05	0.000827	CcSEcCtD
Pazopanib—Skin disorder—Sorafenib—thyroid cancer	4.27e-05	0.000822	CcSEcCtD
Pazopanib—Musculoskeletal pain—Doxorubicin—thyroid cancer	4.26e-05	0.000821	CcSEcCtD
Pazopanib—Pulmonary embolism—Doxorubicin—thyroid cancer	4.21e-05	0.000811	CcSEcCtD
Pazopanib—Hiccups—Doxorubicin—thyroid cancer	4.21e-05	0.000811	CcSEcCtD
Pazopanib—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	4.21e-05	0.000811	CcSEcCtD
Pazopanib—Anorexia—Sorafenib—thyroid cancer	4.19e-05	0.000807	CcSEcCtD
Pazopanib—Vomiting—Vandetanib—thyroid cancer	4.14e-05	0.000798	CcSEcCtD
Pazopanib—Mouth ulceration—Epirubicin—thyroid cancer	4.11e-05	0.000792	CcSEcCtD
Pazopanib—Melaena—Doxorubicin—thyroid cancer	4.11e-05	0.000792	CcSEcCtD
Pazopanib—Rash—Vandetanib—thyroid cancer	4.11e-05	0.000791	CcSEcCtD
Pazopanib—Dermatitis—Vandetanib—thyroid cancer	4.1e-05	0.00079	CcSEcCtD
Pazopanib—Headache—Vandetanib—thyroid cancer	4.08e-05	0.000786	CcSEcCtD
Pazopanib—ABCB1—trachea—thyroid cancer	4.06e-05	0.00175	CbGeAlD
Pazopanib—ABCG2—lymph node—thyroid cancer	4.04e-05	0.00174	CbGeAlD
Pazopanib—Skin exfoliation—Doxorubicin—thyroid cancer	4.02e-05	0.000774	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Sorafenib—thyroid cancer	4e-05	0.000771	CcSEcCtD
Pazopanib—Blood urea increased—Doxorubicin—thyroid cancer	3.98e-05	0.000766	CcSEcCtD
Pazopanib—CYP2D6—head—thyroid cancer	3.96e-05	0.00171	CbGeAlD
Pazopanib—Dyspnoea—Sorafenib—thyroid cancer	3.92e-05	0.000754	CcSEcCtD
Pazopanib—Nausea—Vandetanib—thyroid cancer	3.87e-05	0.000745	CcSEcCtD
Pazopanib—Dyspepsia—Sorafenib—thyroid cancer	3.87e-05	0.000745	CcSEcCtD
Pazopanib—Decreased appetite—Sorafenib—thyroid cancer	3.82e-05	0.000736	CcSEcCtD
Pazopanib—Mouth ulceration—Doxorubicin—thyroid cancer	3.81e-05	0.000733	CcSEcCtD
Pazopanib—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	3.8e-05	0.000731	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Sorafenib—thyroid cancer	3.79e-05	0.00073	CcSEcCtD
Pazopanib—Fatigue—Sorafenib—thyroid cancer	3.79e-05	0.000729	CcSEcCtD
Pazopanib—Hepatic function abnormal—Epirubicin—thyroid cancer	3.78e-05	0.000728	CcSEcCtD
Pazopanib—Pain—Sorafenib—thyroid cancer	3.76e-05	0.000724	CcSEcCtD
Pazopanib—Hepatic failure—Epirubicin—thyroid cancer	3.68e-05	0.000708	CcSEcCtD
Pazopanib—Cardiac failure congestive—Epirubicin—thyroid cancer	3.64e-05	0.000702	CcSEcCtD
Pazopanib—Gastrointestinal pain—Sorafenib—thyroid cancer	3.59e-05	0.000692	CcSEcCtD
Pazopanib—Hot flush—Epirubicin—thyroid cancer	3.53e-05	0.00068	CcSEcCtD
Pazopanib—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	3.51e-05	0.000677	CcSEcCtD
Pazopanib—Menopausal symptoms—Epirubicin—thyroid cancer	3.5e-05	0.000674	CcSEcCtD
Pazopanib—Hepatic function abnormal—Doxorubicin—thyroid cancer	3.5e-05	0.000674	CcSEcCtD
Pazopanib—Abdominal pain—Sorafenib—thyroid cancer	3.47e-05	0.000669	CcSEcCtD
Pazopanib—Hepatic failure—Doxorubicin—thyroid cancer	3.4e-05	0.000655	CcSEcCtD
Pazopanib—Cardiac failure—Epirubicin—thyroid cancer	3.38e-05	0.000652	CcSEcCtD
Pazopanib—Lethargy—Epirubicin—thyroid cancer	3.37e-05	0.000649	CcSEcCtD
Pazopanib—Cerebrovascular accident—Epirubicin—thyroid cancer	3.37e-05	0.000649	CcSEcCtD
Pazopanib—Cardiac failure congestive—Doxorubicin—thyroid cancer	3.37e-05	0.000649	CcSEcCtD
Pazopanib—Hyponatraemia—Epirubicin—thyroid cancer	3.32e-05	0.000639	CcSEcCtD
Pazopanib—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	3.3e-05	0.000636	CcSEcCtD
Pazopanib—Hot flush—Doxorubicin—thyroid cancer	3.27e-05	0.000629	CcSEcCtD
Pazopanib—Menopausal symptoms—Doxorubicin—thyroid cancer	3.24e-05	0.000624	CcSEcCtD
Pazopanib—ABCB1—thyroid gland—thyroid cancer	3.21e-05	0.00138	CbGeAlD
Pazopanib—Face oedema—Epirubicin—thyroid cancer	3.19e-05	0.000614	CcSEcCtD
Pazopanib—Asthenia—Sorafenib—thyroid cancer	3.15e-05	0.000607	CcSEcCtD
Pazopanib—Cardiac failure—Doxorubicin—thyroid cancer	3.13e-05	0.000603	CcSEcCtD
Pazopanib—Cerebrovascular accident—Doxorubicin—thyroid cancer	3.12e-05	0.000601	CcSEcCtD
Pazopanib—Lethargy—Doxorubicin—thyroid cancer	3.12e-05	0.000601	CcSEcCtD
Pazopanib—Pruritus—Sorafenib—thyroid cancer	3.11e-05	0.000599	CcSEcCtD
Pazopanib—Blood creatinine increased—Epirubicin—thyroid cancer	3.09e-05	0.000596	CcSEcCtD
Pazopanib—Dehydration—Epirubicin—thyroid cancer	3.07e-05	0.000592	CcSEcCtD
Pazopanib—Hyponatraemia—Doxorubicin—thyroid cancer	3.07e-05	0.000591	CcSEcCtD
Pazopanib—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	3.06e-05	0.000589	CcSEcCtD
Pazopanib—Liver function test abnormal—Epirubicin—thyroid cancer	3.05e-05	0.000587	CcSEcCtD
Pazopanib—Dry skin—Epirubicin—thyroid cancer	3.03e-05	0.000583	CcSEcCtD
Pazopanib—Abdominal pain upper—Epirubicin—thyroid cancer	3.02e-05	0.000581	CcSEcCtD
Pazopanib—Diarrhoea—Sorafenib—thyroid cancer	3.01e-05	0.000579	CcSEcCtD
Pazopanib—Breast disorder—Epirubicin—thyroid cancer	2.98e-05	0.000575	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	2.97e-05	0.000573	CcSEcCtD
Pazopanib—Nasopharyngitis—Epirubicin—thyroid cancer	2.95e-05	0.000569	CcSEcCtD
Pazopanib—Face oedema—Doxorubicin—thyroid cancer	2.95e-05	0.000568	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Epirubicin—thyroid cancer	2.91e-05	0.000561	CcSEcCtD
Pazopanib—Dizziness—Sorafenib—thyroid cancer	2.9e-05	0.00056	CcSEcCtD
Pazopanib—Abdominal distension—Epirubicin—thyroid cancer	2.87e-05	0.000554	CcSEcCtD
Pazopanib—Blood creatinine increased—Doxorubicin—thyroid cancer	2.86e-05	0.000552	CcSEcCtD
Pazopanib—ABCB1—head—thyroid cancer	2.85e-05	0.00123	CbGeAlD
Pazopanib—Dehydration—Doxorubicin—thyroid cancer	2.84e-05	0.000547	CcSEcCtD
Pazopanib—Liver function test abnormal—Doxorubicin—thyroid cancer	2.82e-05	0.000544	CcSEcCtD
Pazopanib—Dry skin—Doxorubicin—thyroid cancer	2.8e-05	0.00054	CcSEcCtD
Pazopanib—Pancreatitis—Epirubicin—thyroid cancer	2.8e-05	0.000539	CcSEcCtD
Pazopanib—Vomiting—Sorafenib—thyroid cancer	2.79e-05	0.000538	CcSEcCtD
Pazopanib—Abdominal pain upper—Doxorubicin—thyroid cancer	2.79e-05	0.000538	CcSEcCtD
Pazopanib—Rash—Sorafenib—thyroid cancer	2.77e-05	0.000534	CcSEcCtD
Pazopanib—Dermatitis—Sorafenib—thyroid cancer	2.77e-05	0.000533	CcSEcCtD
Pazopanib—Breast disorder—Doxorubicin—thyroid cancer	2.76e-05	0.000532	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	2.75e-05	0.00053	CcSEcCtD
Pazopanib—Headache—Sorafenib—thyroid cancer	2.75e-05	0.00053	CcSEcCtD
Pazopanib—Nasopharyngitis—Doxorubicin—thyroid cancer	2.73e-05	0.000526	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	2.7e-05	0.000519	CcSEcCtD
Pazopanib—Neutropenia—Epirubicin—thyroid cancer	2.67e-05	0.000514	CcSEcCtD
Pazopanib—Abdominal distension—Doxorubicin—thyroid cancer	2.66e-05	0.000512	CcSEcCtD
Pazopanib—Nausea—Sorafenib—thyroid cancer	2.61e-05	0.000503	CcSEcCtD
Pazopanib—Photosensitivity reaction—Epirubicin—thyroid cancer	2.61e-05	0.000502	CcSEcCtD
Pazopanib—Pancreatitis—Doxorubicin—thyroid cancer	2.59e-05	0.000499	CcSEcCtD
Pazopanib—Weight decreased—Epirubicin—thyroid cancer	2.58e-05	0.000497	CcSEcCtD
Pazopanib—Infestation—Epirubicin—thyroid cancer	2.55e-05	0.00049	CcSEcCtD
Pazopanib—Infestation NOS—Epirubicin—thyroid cancer	2.55e-05	0.00049	CcSEcCtD
Pazopanib—Jaundice—Epirubicin—thyroid cancer	2.48e-05	0.000478	CcSEcCtD
Pazopanib—Stomatitis—Epirubicin—thyroid cancer	2.48e-05	0.000478	CcSEcCtD
Pazopanib—Neutropenia—Doxorubicin—thyroid cancer	2.47e-05	0.000476	CcSEcCtD
Pazopanib—Haematuria—Epirubicin—thyroid cancer	2.43e-05	0.000467	CcSEcCtD
Pazopanib—Photosensitivity reaction—Doxorubicin—thyroid cancer	2.41e-05	0.000464	CcSEcCtD
Pazopanib—Hepatobiliary disease—Epirubicin—thyroid cancer	2.41e-05	0.000464	CcSEcCtD
Pazopanib—Epistaxis—Epirubicin—thyroid cancer	2.4e-05	0.000462	CcSEcCtD
Pazopanib—Weight decreased—Doxorubicin—thyroid cancer	2.39e-05	0.00046	CcSEcCtD
Pazopanib—Infestation NOS—Doxorubicin—thyroid cancer	2.36e-05	0.000454	CcSEcCtD
Pazopanib—Infestation—Doxorubicin—thyroid cancer	2.36e-05	0.000454	CcSEcCtD
Pazopanib—Bradycardia—Epirubicin—thyroid cancer	2.33e-05	0.000448	CcSEcCtD
Pazopanib—Haemoglobin—Epirubicin—thyroid cancer	2.3e-05	0.000442	CcSEcCtD
Pazopanib—Jaundice—Doxorubicin—thyroid cancer	2.3e-05	0.000442	CcSEcCtD
Pazopanib—Stomatitis—Doxorubicin—thyroid cancer	2.3e-05	0.000442	CcSEcCtD
Pazopanib—Haemorrhage—Epirubicin—thyroid cancer	2.29e-05	0.00044	CcSEcCtD
Pazopanib—Hypoaesthesia—Epirubicin—thyroid cancer	2.27e-05	0.000438	CcSEcCtD
Pazopanib—Urinary tract disorder—Epirubicin—thyroid cancer	2.26e-05	0.000435	CcSEcCtD
Pazopanib—Oedema peripheral—Epirubicin—thyroid cancer	2.25e-05	0.000434	CcSEcCtD
Pazopanib—Haematuria—Doxorubicin—thyroid cancer	2.25e-05	0.000433	CcSEcCtD
Pazopanib—Connective tissue disorder—Epirubicin—thyroid cancer	2.25e-05	0.000433	CcSEcCtD
Pazopanib—Urethral disorder—Epirubicin—thyroid cancer	2.24e-05	0.000431	CcSEcCtD
Pazopanib—Hepatobiliary disease—Doxorubicin—thyroid cancer	2.23e-05	0.000429	CcSEcCtD
Pazopanib—Epistaxis—Doxorubicin—thyroid cancer	2.22e-05	0.000428	CcSEcCtD
Pazopanib—Bradycardia—Doxorubicin—thyroid cancer	2.15e-05	0.000415	CcSEcCtD
Pazopanib—Eye disorder—Epirubicin—thyroid cancer	2.14e-05	0.000411	CcSEcCtD
Pazopanib—Haemoglobin—Doxorubicin—thyroid cancer	2.13e-05	0.000409	CcSEcCtD
Pazopanib—Flushing—Epirubicin—thyroid cancer	2.12e-05	0.000408	CcSEcCtD
Pazopanib—Cardiac disorder—Epirubicin—thyroid cancer	2.12e-05	0.000408	CcSEcCtD
Pazopanib—Haemorrhage—Doxorubicin—thyroid cancer	2.11e-05	0.000407	CcSEcCtD
Pazopanib—Hypoaesthesia—Doxorubicin—thyroid cancer	2.1e-05	0.000405	CcSEcCtD
Pazopanib—Urinary tract disorder—Doxorubicin—thyroid cancer	2.09e-05	0.000402	CcSEcCtD
Pazopanib—Oedema peripheral—Doxorubicin—thyroid cancer	2.08e-05	0.000401	CcSEcCtD
Pazopanib—Connective tissue disorder—Doxorubicin—thyroid cancer	2.08e-05	0.0004	CcSEcCtD
Pazopanib—Angiopathy—Epirubicin—thyroid cancer	2.07e-05	0.000399	CcSEcCtD
Pazopanib—Urethral disorder—Doxorubicin—thyroid cancer	2.07e-05	0.000399	CcSEcCtD
Pazopanib—Mediastinal disorder—Epirubicin—thyroid cancer	2.06e-05	0.000397	CcSEcCtD
Pazopanib—Chills—Epirubicin—thyroid cancer	2.05e-05	0.000395	CcSEcCtD
Pazopanib—Alopecia—Epirubicin—thyroid cancer	2.02e-05	0.000389	CcSEcCtD
Pazopanib—Mental disorder—Epirubicin—thyroid cancer	2e-05	0.000386	CcSEcCtD
Pazopanib—ABCB1—lymph node—thyroid cancer	1.99e-05	0.000859	CbGeAlD
Pazopanib—Erythema—Epirubicin—thyroid cancer	1.99e-05	0.000383	CcSEcCtD
Pazopanib—Malnutrition—Epirubicin—thyroid cancer	1.99e-05	0.000383	CcSEcCtD
Pazopanib—Eye disorder—Doxorubicin—thyroid cancer	1.98e-05	0.000381	CcSEcCtD
Pazopanib—Flushing—Doxorubicin—thyroid cancer	1.96e-05	0.000378	CcSEcCtD
Pazopanib—Cardiac disorder—Doxorubicin—thyroid cancer	1.96e-05	0.000378	CcSEcCtD
Pazopanib—Flatulence—Epirubicin—thyroid cancer	1.96e-05	0.000378	CcSEcCtD
Pazopanib—Dysgeusia—Epirubicin—thyroid cancer	1.95e-05	0.000375	CcSEcCtD
Pazopanib—Angiopathy—Doxorubicin—thyroid cancer	1.92e-05	0.000369	CcSEcCtD
Pazopanib—Muscle spasms—Epirubicin—thyroid cancer	1.91e-05	0.000368	CcSEcCtD
Pazopanib—Mediastinal disorder—Doxorubicin—thyroid cancer	1.91e-05	0.000367	CcSEcCtD
Pazopanib—Chills—Doxorubicin—thyroid cancer	1.9e-05	0.000365	CcSEcCtD
Pazopanib—Vision blurred—Epirubicin—thyroid cancer	1.87e-05	0.000361	CcSEcCtD
Pazopanib—Alopecia—Doxorubicin—thyroid cancer	1.87e-05	0.00036	CcSEcCtD
Pazopanib—Mental disorder—Doxorubicin—thyroid cancer	1.85e-05	0.000357	CcSEcCtD
Pazopanib—Malnutrition—Doxorubicin—thyroid cancer	1.84e-05	0.000355	CcSEcCtD
Pazopanib—Erythema—Doxorubicin—thyroid cancer	1.84e-05	0.000355	CcSEcCtD
Pazopanib—Anaemia—Epirubicin—thyroid cancer	1.84e-05	0.000354	CcSEcCtD
Pazopanib—Flatulence—Doxorubicin—thyroid cancer	1.81e-05	0.000349	CcSEcCtD
Pazopanib—Dysgeusia—Doxorubicin—thyroid cancer	1.8e-05	0.000347	CcSEcCtD
Pazopanib—Syncope—Epirubicin—thyroid cancer	1.78e-05	0.000344	CcSEcCtD
Pazopanib—Leukopenia—Epirubicin—thyroid cancer	1.78e-05	0.000343	CcSEcCtD
Pazopanib—Muscle spasms—Doxorubicin—thyroid cancer	1.77e-05	0.000341	CcSEcCtD
Pazopanib—Loss of consciousness—Epirubicin—thyroid cancer	1.75e-05	0.000337	CcSEcCtD
Pazopanib—Cough—Epirubicin—thyroid cancer	1.74e-05	0.000334	CcSEcCtD
Pazopanib—Vision blurred—Doxorubicin—thyroid cancer	1.73e-05	0.000334	CcSEcCtD
Pazopanib—Hypertension—Epirubicin—thyroid cancer	1.72e-05	0.000331	CcSEcCtD
Pazopanib—Anaemia—Doxorubicin—thyroid cancer	1.7e-05	0.000328	CcSEcCtD
Pazopanib—Arthralgia—Epirubicin—thyroid cancer	1.69e-05	0.000326	CcSEcCtD
Pazopanib—Chest pain—Epirubicin—thyroid cancer	1.69e-05	0.000326	CcSEcCtD
Pazopanib—Myalgia—Epirubicin—thyroid cancer	1.69e-05	0.000326	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	1.68e-05	0.000324	CcSEcCtD
Pazopanib—Dry mouth—Epirubicin—thyroid cancer	1.66e-05	0.000319	CcSEcCtD
Pazopanib—Syncope—Doxorubicin—thyroid cancer	1.65e-05	0.000318	CcSEcCtD
Pazopanib—Leukopenia—Doxorubicin—thyroid cancer	1.65e-05	0.000317	CcSEcCtD
Pazopanib—Oedema—Epirubicin—thyroid cancer	1.62e-05	0.000313	CcSEcCtD
Pazopanib—Loss of consciousness—Doxorubicin—thyroid cancer	1.62e-05	0.000312	CcSEcCtD
Pazopanib—Infection—Epirubicin—thyroid cancer	1.61e-05	0.000311	CcSEcCtD
Pazopanib—Cough—Doxorubicin—thyroid cancer	1.61e-05	0.000309	CcSEcCtD
Pazopanib—Shock—Epirubicin—thyroid cancer	1.6e-05	0.000308	CcSEcCtD
Pazopanib—Nervous system disorder—Epirubicin—thyroid cancer	1.59e-05	0.000307	CcSEcCtD
Pazopanib—Thrombocytopenia—Epirubicin—thyroid cancer	1.59e-05	0.000306	CcSEcCtD
Pazopanib—Hypertension—Doxorubicin—thyroid cancer	1.59e-05	0.000306	CcSEcCtD
Pazopanib—Skin disorder—Epirubicin—thyroid cancer	1.58e-05	0.000304	CcSEcCtD
Pazopanib—Hyperhidrosis—Epirubicin—thyroid cancer	1.57e-05	0.000302	CcSEcCtD
Pazopanib—Myalgia—Doxorubicin—thyroid cancer	1.57e-05	0.000302	CcSEcCtD
Pazopanib—Arthralgia—Doxorubicin—thyroid cancer	1.57e-05	0.000302	CcSEcCtD
Pazopanib—Chest pain—Doxorubicin—thyroid cancer	1.57e-05	0.000302	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	1.56e-05	0.0003	CcSEcCtD
Pazopanib—Anorexia—Epirubicin—thyroid cancer	1.55e-05	0.000298	CcSEcCtD
Pazopanib—Dry mouth—Doxorubicin—thyroid cancer	1.53e-05	0.000295	CcSEcCtD
Pazopanib—Oedema—Doxorubicin—thyroid cancer	1.5e-05	0.000289	CcSEcCtD
Pazopanib—Infection—Doxorubicin—thyroid cancer	1.49e-05	0.000287	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Epirubicin—thyroid cancer	1.48e-05	0.000285	CcSEcCtD
Pazopanib—Shock—Doxorubicin—thyroid cancer	1.48e-05	0.000285	CcSEcCtD
Pazopanib—Nervous system disorder—Doxorubicin—thyroid cancer	1.47e-05	0.000284	CcSEcCtD
Pazopanib—Thrombocytopenia—Doxorubicin—thyroid cancer	1.47e-05	0.000283	CcSEcCtD
Pazopanib—Insomnia—Epirubicin—thyroid cancer	1.47e-05	0.000283	CcSEcCtD
Pazopanib—Skin disorder—Doxorubicin—thyroid cancer	1.46e-05	0.000281	CcSEcCtD
Pazopanib—Paraesthesia—Epirubicin—thyroid cancer	1.46e-05	0.000281	CcSEcCtD
Pazopanib—Hyperhidrosis—Doxorubicin—thyroid cancer	1.45e-05	0.00028	CcSEcCtD
Pazopanib—Dyspnoea—Epirubicin—thyroid cancer	1.45e-05	0.000279	CcSEcCtD
Pazopanib—Somnolence—Epirubicin—thyroid cancer	1.44e-05	0.000278	CcSEcCtD
Pazopanib—Anorexia—Doxorubicin—thyroid cancer	1.43e-05	0.000276	CcSEcCtD
Pazopanib—Dyspepsia—Epirubicin—thyroid cancer	1.43e-05	0.000275	CcSEcCtD
Pazopanib—Decreased appetite—Epirubicin—thyroid cancer	1.41e-05	0.000272	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Epirubicin—thyroid cancer	1.4e-05	0.00027	CcSEcCtD
Pazopanib—Fatigue—Epirubicin—thyroid cancer	1.4e-05	0.00027	CcSEcCtD
Pazopanib—Pain—Epirubicin—thyroid cancer	1.39e-05	0.000267	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	1.37e-05	0.000264	CcSEcCtD
Pazopanib—Insomnia—Doxorubicin—thyroid cancer	1.36e-05	0.000262	CcSEcCtD
Pazopanib—Paraesthesia—Doxorubicin—thyroid cancer	1.35e-05	0.00026	CcSEcCtD
Pazopanib—Dyspnoea—Doxorubicin—thyroid cancer	1.34e-05	0.000258	CcSEcCtD
Pazopanib—Somnolence—Doxorubicin—thyroid cancer	1.34e-05	0.000257	CcSEcCtD
Pazopanib—Gastrointestinal pain—Epirubicin—thyroid cancer	1.33e-05	0.000256	CcSEcCtD
Pazopanib—Dyspepsia—Doxorubicin—thyroid cancer	1.32e-05	0.000255	CcSEcCtD
Pazopanib—Decreased appetite—Doxorubicin—thyroid cancer	1.31e-05	0.000252	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Doxorubicin—thyroid cancer	1.3e-05	0.00025	CcSEcCtD
Pazopanib—Fatigue—Doxorubicin—thyroid cancer	1.3e-05	0.000249	CcSEcCtD
Pazopanib—Pain—Doxorubicin—thyroid cancer	1.28e-05	0.000247	CcSEcCtD
Pazopanib—Abdominal pain—Epirubicin—thyroid cancer	1.28e-05	0.000247	CcSEcCtD
Pazopanib—Gastrointestinal pain—Doxorubicin—thyroid cancer	1.23e-05	0.000237	CcSEcCtD
Pazopanib—Abdominal pain—Doxorubicin—thyroid cancer	1.19e-05	0.000229	CcSEcCtD
Pazopanib—Asthenia—Epirubicin—thyroid cancer	1.16e-05	0.000224	CcSEcCtD
Pazopanib—Pruritus—Epirubicin—thyroid cancer	1.15e-05	0.000221	CcSEcCtD
Pazopanib—Diarrhoea—Epirubicin—thyroid cancer	1.11e-05	0.000214	CcSEcCtD
Pazopanib—Asthenia—Doxorubicin—thyroid cancer	1.08e-05	0.000208	CcSEcCtD
Pazopanib—Dizziness—Epirubicin—thyroid cancer	1.07e-05	0.000207	CcSEcCtD
Pazopanib—Pruritus—Doxorubicin—thyroid cancer	1.06e-05	0.000205	CcSEcCtD
Pazopanib—Vomiting—Epirubicin—thyroid cancer	1.03e-05	0.000199	CcSEcCtD
Pazopanib—Diarrhoea—Doxorubicin—thyroid cancer	1.03e-05	0.000198	CcSEcCtD
Pazopanib—Rash—Epirubicin—thyroid cancer	1.02e-05	0.000197	CcSEcCtD
Pazopanib—Dermatitis—Epirubicin—thyroid cancer	1.02e-05	0.000197	CcSEcCtD
Pazopanib—Headache—Epirubicin—thyroid cancer	1.02e-05	0.000196	CcSEcCtD
Pazopanib—Dizziness—Doxorubicin—thyroid cancer	9.93e-06	0.000191	CcSEcCtD
Pazopanib—Nausea—Epirubicin—thyroid cancer	9.64e-06	0.000186	CcSEcCtD
Pazopanib—Vomiting—Doxorubicin—thyroid cancer	9.55e-06	0.000184	CcSEcCtD
Pazopanib—Rash—Doxorubicin—thyroid cancer	9.47e-06	0.000182	CcSEcCtD
Pazopanib—Dermatitis—Doxorubicin—thyroid cancer	9.46e-06	0.000182	CcSEcCtD
Pazopanib—Headache—Doxorubicin—thyroid cancer	9.41e-06	0.000181	CcSEcCtD
Pazopanib—Nausea—Doxorubicin—thyroid cancer	8.92e-06	0.000172	CcSEcCtD
Pazopanib—PDGFRB—Signaling Pathways—TERT—thyroid cancer	1.52e-06	3.8e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—AKT1—thyroid cancer	1.48e-06	3.72e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TERT—thyroid cancer	1.48e-06	3.72e-05	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—AKT1—thyroid cancer	1.48e-06	3.72e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—HRAS—thyroid cancer	1.48e-06	3.71e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—KRAS—thyroid cancer	1.48e-06	3.7e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—TPR—thyroid cancer	1.47e-06	3.68e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—PTEN—thyroid cancer	1.47e-06	3.68e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—HRAS—thyroid cancer	1.47e-06	3.67e-05	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—AKT1—thyroid cancer	1.46e-06	3.65e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—PTEN—thyroid cancer	1.46e-06	3.65e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—PTEN—thyroid cancer	1.45e-06	3.64e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—HIF1A—thyroid cancer	1.45e-06	3.63e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—KRAS—thyroid cancer	1.45e-06	3.63e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	1.45e-06	3.63e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—PTEN—thyroid cancer	1.44e-06	3.61e-05	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—AKT1—thyroid cancer	1.44e-06	3.61e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—AKT1—thyroid cancer	1.44e-06	3.6e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—HRAS—thyroid cancer	1.43e-06	3.6e-05	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—AKT1—thyroid cancer	1.43e-06	3.6e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—BRAF—thyroid cancer	1.43e-06	3.59e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—HIF1A—thyroid cancer	1.42e-06	3.56e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—PTEN—thyroid cancer	1.42e-06	3.55e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—BRAF—thyroid cancer	1.41e-06	3.53e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—HRAS—thyroid cancer	1.41e-06	3.53e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—AKT1—thyroid cancer	1.41e-06	3.53e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—NRAS—thyroid cancer	1.39e-06	3.49e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—PTGS2—thyroid cancer	1.38e-06	3.47e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—KRAS—thyroid cancer	1.38e-06	3.47e-05	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—AKT1—thyroid cancer	1.38e-06	3.47e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—AKT1—thyroid cancer	1.38e-06	3.46e-05	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—HRAS—thyroid cancer	1.38e-06	3.45e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—BRAF—thyroid cancer	1.38e-06	3.45e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—NRAS—thyroid cancer	1.37e-06	3.43e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—HRAS—thyroid cancer	1.37e-06	3.43e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—TP53—thyroid cancer	1.37e-06	3.42e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—CCND1—thyroid cancer	1.36e-06	3.41e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NRG1—thyroid cancer	1.35e-06	3.4e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PPARG—thyroid cancer	1.35e-06	3.39e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—PTEN—thyroid cancer	1.34e-06	3.37e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—SLC5A5—thyroid cancer	1.34e-06	3.36e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—PTEN—thyroid cancer	1.34e-06	3.36e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—KRAS—thyroid cancer	1.34e-06	3.35e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—BRAF—thyroid cancer	1.34e-06	3.35e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—BRAF—thyroid cancer	1.33e-06	3.34e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—KRAS—thyroid cancer	1.33e-06	3.33e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—CCND1—thyroid cancer	1.32e-06	3.32e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.32e-06	3.3e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—PTEN—thyroid cancer	1.31e-06	3.29e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—TP53—thyroid cancer	1.31e-06	3.29e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—NRAS—thyroid cancer	1.31e-06	3.28e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—AKT1—thyroid cancer	1.31e-06	3.28e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—PTEN—thyroid cancer	1.31e-06	3.28e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—HRAS—thyroid cancer	1.31e-06	3.27e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—NRAS—thyroid cancer	1.3e-06	3.25e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—NRAS—thyroid cancer	1.29e-06	3.25e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—AKT1—thyroid cancer	1.29e-06	3.24e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—NRAS—thyroid cancer	1.29e-06	3.22e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—PTEN—thyroid cancer	1.28e-06	3.21e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—PTEN—thyroid cancer	1.28e-06	3.21e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—AKT1—thyroid cancer	1.27e-06	3.18e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CCND1—thyroid cancer	1.26e-06	3.17e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—NRAS—thyroid cancer	1.26e-06	3.17e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.26e-06	3.15e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—HRAS—thyroid cancer	1.25e-06	3.14e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—TPR—thyroid cancer	1.25e-06	3.12e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—AKT1—thyroid cancer	1.24e-06	3.11e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PPARG—thyroid cancer	1.24e-06	3.1e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—HRAS—thyroid cancer	1.23e-06	3.09e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	1.23e-06	3.07e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—PTEN—thyroid cancer	1.22e-06	3.06e-05	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—AKT1—thyroid cancer	1.22e-06	3.05e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TERT—thyroid cancer	1.22e-06	3.05e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—AKT1—thyroid cancer	1.21e-06	3.03e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—PTEN—thyroid cancer	1.21e-06	3.03e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—BRAF—thyroid cancer	1.2e-06	3.01e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—KRAS—thyroid cancer	1.2e-06	3.01e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—NRAS—thyroid cancer	1.2e-06	3e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—NRAS—thyroid cancer	1.2e-06	3e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—KRAS—thyroid cancer	1.18e-06	2.95e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—HRAS—thyroid cancer	1.18e-06	2.95e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—BRAF—thyroid cancer	1.18e-06	2.95e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—NRAS—thyroid cancer	1.17e-06	2.93e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.17e-06	2.93e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—NRAS—thyroid cancer	1.17e-06	2.92e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HIF1A—thyroid cancer	1.16e-06	2.92e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—AKT1—thyroid cancer	1.15e-06	2.89e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PPARG—thyroid cancer	1.15e-06	2.87e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—NRAS—thyroid cancer	1.14e-06	2.86e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—NRAS—thyroid cancer	1.14e-06	2.86e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—HRAS—thyroid cancer	1.14e-06	2.85e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—HRAS—thyroid cancer	1.13e-06	2.83e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—KRAS—thyroid cancer	1.13e-06	2.83e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—RXRA—thyroid cancer	1.13e-06	2.82e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—KRAS—thyroid cancer	1.12e-06	2.8e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—KRAS—thyroid cancer	1.11e-06	2.79e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—PTGS2—thyroid cancer	1.11e-06	2.78e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.11e-06	2.78e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—AKT1—thyroid cancer	1.11e-06	2.78e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—KRAS—thyroid cancer	1.11e-06	2.77e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—SLC5A5—thyroid cancer	1.1e-06	2.76e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.1e-06	2.75e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—NRAS—thyroid cancer	1.09e-06	2.73e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—AKT1—thyroid cancer	1.09e-06	2.73e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—KRAS—thyroid cancer	1.09e-06	2.73e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—NRAS—thyroid cancer	1.08e-06	2.7e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PTGS2—thyroid cancer	1.06e-06	2.66e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—PTEN—thyroid cancer	1.05e-06	2.63e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CCND1—thyroid cancer	1.05e-06	2.62e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—AKT1—thyroid cancer	1.04e-06	2.6e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—KRAS—thyroid cancer	1.03e-06	2.59e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—KRAS—thyroid cancer	1.03e-06	2.58e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CCND1—thyroid cancer	1.03e-06	2.57e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—HRAS—thyroid cancer	1.02e-06	2.55e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PTEN—thyroid cancer	1.01e-06	2.53e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—KRAS—thyroid cancer	1.01e-06	2.53e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—KRAS—thyroid cancer	1e-06	2.52e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—AKT1—thyroid cancer	1e-06	2.52e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TP53—thyroid cancer	1e-06	2.51e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—HRAS—thyroid cancer	1e-06	2.51e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—AKT1—thyroid cancer	9.97e-07	2.5e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PTEN—thyroid cancer	9.91e-07	2.49e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—KRAS—thyroid cancer	9.83e-07	2.46e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—KRAS—thyroid cancer	9.82e-07	2.46e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—RXRA—thyroid cancer	9.81e-07	2.46e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CCND1—thyroid cancer	9.75e-07	2.44e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTGS2—thyroid cancer	9.73e-07	2.44e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CCND1—thyroid cancer	9.72e-07	2.44e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—PTEN—thyroid cancer	9.69e-07	2.43e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—BRAF—thyroid cancer	9.63e-07	2.41e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—TPR—thyroid cancer	9.61e-07	2.41e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—HRAS—thyroid cancer	9.58e-07	2.4e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—HRAS—thyroid cancer	9.5e-07	2.38e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—HRAS—thyroid cancer	9.47e-07	2.37e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	9.46e-07	2.37e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PTEN—thyroid cancer	9.41e-07	2.36e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—HRAS—thyroid cancer	9.41e-07	2.36e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PTEN—thyroid cancer	9.38e-07	2.35e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—KRAS—thyroid cancer	9.37e-07	2.35e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—NRAS—thyroid cancer	9.36e-07	2.35e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—SLC5A5—thyroid cancer	9.32e-07	2.34e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—KRAS—thyroid cancer	9.27e-07	2.32e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PTEN—thyroid cancer	9.26e-07	2.32e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—RXRA—thyroid cancer	9.25e-07	2.32e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—HRAS—thyroid cancer	9.24e-07	2.32e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTGS2—thyroid cancer	9.01e-07	2.26e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—NRAS—thyroid cancer	9.01e-07	2.26e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—AKT1—thyroid cancer	9e-07	2.26e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—thyroid cancer	8.95e-07	2.24e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—NRAS—thyroid cancer	8.84e-07	2.22e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—AKT1—thyroid cancer	8.84e-07	2.22e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—HRAS—thyroid cancer	8.77e-07	2.2e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCND1—thyroid cancer	8.76e-07	2.2e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—HRAS—thyroid cancer	8.75e-07	2.19e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	8.74e-07	2.19e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—thyroid cancer	8.73e-07	2.19e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—NRAS—thyroid cancer	8.64e-07	2.17e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCND1—thyroid cancer	8.58e-07	2.15e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—HRAS—thyroid cancer	8.56e-07	2.15e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HRAS—thyroid cancer	8.53e-07	2.14e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTEN—thyroid cancer	8.49e-07	2.13e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—AKT1—thyroid cancer	8.46e-07	2.12e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PTEN—thyroid cancer	8.45e-07	2.12e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—NRAS—thyroid cancer	8.39e-07	2.1e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—AKT1—thyroid cancer	8.39e-07	2.1e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—NRAS—thyroid cancer	8.37e-07	2.1e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—AKT1—thyroid cancer	8.37e-07	2.1e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—HRAS—thyroid cancer	8.36e-07	2.09e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—HRAS—thyroid cancer	8.35e-07	2.09e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—thyroid cancer	8.32e-07	2.09e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—AKT1—thyroid cancer	8.31e-07	2.08e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PTEN—thyroid cancer	8.28e-07	2.07e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—AKT1—thyroid cancer	8.16e-07	2.05e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—KRAS—thyroid cancer	8.06e-07	2.02e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—HRAS—thyroid cancer	7.96e-07	2e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—HRAS—thyroid cancer	7.88e-07	1.98e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTEN—thyroid cancer	7.86e-07	1.97e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—RXRA—thyroid cancer	7.83e-07	1.96e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—KRAS—thyroid cancer	7.75e-07	1.94e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—AKT1—thyroid cancer	7.74e-07	1.94e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—AKT1—thyroid cancer	7.72e-07	1.94e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	7.62e-07	1.91e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—KRAS—thyroid cancer	7.61e-07	1.91e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—AKT1—thyroid cancer	7.56e-07	1.9e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NRAS—thyroid cancer	7.54e-07	1.89e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—AKT1—thyroid cancer	7.54e-07	1.89e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—KRAS—thyroid cancer	7.44e-07	1.86e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NRAS—thyroid cancer	7.38e-07	1.85e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—AKT1—thyroid cancer	7.38e-07	1.85e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—AKT1—thyroid cancer	7.37e-07	1.85e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—KRAS—thyroid cancer	7.22e-07	1.81e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—KRAS—thyroid cancer	7.21e-07	1.81e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SLC5A5—thyroid cancer	7.19e-07	1.8e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PPARG—thyroid cancer	7.11e-07	1.78e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCND1—thyroid cancer	7.03e-07	1.76e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—AKT1—thyroid cancer	7.03e-07	1.76e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—AKT1—thyroid cancer	6.96e-07	1.74e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—thyroid cancer	6.89e-07	1.73e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—HRAS—thyroid cancer	6.85e-07	1.72e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PTEN—thyroid cancer	6.78e-07	1.7e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—thyroid cancer	6.77e-07	1.7e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—HRAS—thyroid cancer	6.59e-07	1.65e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KRAS—thyroid cancer	6.49e-07	1.63e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—HRAS—thyroid cancer	6.47e-07	1.62e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—thyroid cancer	6.42e-07	1.61e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—thyroid cancer	6.4e-07	1.61e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KRAS—thyroid cancer	6.36e-07	1.59e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—HRAS—thyroid cancer	6.32e-07	1.59e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PPARG—thyroid cancer	6.19e-07	1.55e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—HRAS—thyroid cancer	6.14e-07	1.54e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—HRAS—thyroid cancer	6.13e-07	1.54e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NRAS—thyroid cancer	6.05e-07	1.52e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—AKT1—thyroid cancer	6.05e-07	1.52e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—RXRA—thyroid cancer	6.04e-07	1.52e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PPARG—thyroid cancer	5.84e-07	1.46e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—AKT1—thyroid cancer	5.82e-07	1.46e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—thyroid cancer	5.77e-07	1.45e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—AKT1—thyroid cancer	5.71e-07	1.43e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—thyroid cancer	5.65e-07	1.42e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTGS2—thyroid cancer	5.59e-07	1.4e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—AKT1—thyroid cancer	5.58e-07	1.4e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—HRAS—thyroid cancer	5.52e-07	1.38e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—AKT1—thyroid cancer	5.42e-07	1.36e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—AKT1—thyroid cancer	5.41e-07	1.36e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—HRAS—thyroid cancer	5.4e-07	1.35e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—AKT1—thyroid cancer	5.34e-07	1.34e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KRAS—thyroid cancer	5.21e-07	1.31e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PPARG—thyroid cancer	4.95e-07	1.24e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—AKT1—thyroid cancer	4.89e-07	1.23e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTEN—thyroid cancer	4.88e-07	1.22e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTGS2—thyroid cancer	4.87e-07	1.22e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—AKT1—thyroid cancer	4.87e-07	1.22e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—AKT1—thyroid cancer	4.77e-07	1.2e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—thyroid cancer	4.63e-07	1.16e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTGS2—thyroid cancer	4.59e-07	1.15e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—AKT1—thyroid cancer	4.53e-07	1.14e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HRAS—thyroid cancer	4.43e-07	1.11e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTEN—thyroid cancer	4.25e-07	1.07e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTEN—thyroid cancer	4e-07	1e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—AKT1—thyroid cancer	3.91e-07	9.8e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTGS2—thyroid cancer	3.89e-07	9.75e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PPARG—thyroid cancer	3.82e-07	9.57e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTEN—thyroid cancer	3.39e-07	8.5e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTGS2—thyroid cancer	3e-07	7.53e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—AKT1—thyroid cancer	2.81e-07	7.05e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTEN—thyroid cancer	2.62e-07	6.56e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—AKT1—thyroid cancer	2.45e-07	6.14e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AKT1—thyroid cancer	2.31e-07	5.79e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AKT1—thyroid cancer	1.96e-07	4.9e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AKT1—thyroid cancer	1.51e-07	3.78e-06	CbGpPWpGaD
